Mizoguchi Takanori, Ozaki Mineo, Wakiyama Harumi, Ogino Nobuchika
Mizoguchi Eye Clinic, Sasebo.
Clin Ophthalmol. 2011;5:1515-20. doi: 10.2147/OPTH.S24058. Epub 2011 Oct 14.
To evaluate the intraocular pressure (IOP)-lowering effect of adding dorzolamide 1.0%/timolol 0.5% fixed combination (DTFC) to prostaglandin analogs (PGAs) as monotherapy in patients with normal tension glaucoma.
A prospective, clinical, case-controlled study of patients with normal tension glaucoma. Patients had been on a once-daily night dose of prostaglandins (PGs) as monotherapy and then received DTFC added to PGs for 8 weeks. The IOP was measured at 9 am, week 0 (baseline), week 4, and week 8.
The baseline IOP of 40 patients who had previously been treated by prostaglandin monotherapy was 15.6 ± 2.0 mmHg at baseline. The IOPs at 4 and 8 weeks after adding DTFC to PGs were 13.5 ± 2.1 mmHg and 13.7 ± 2.2 mmHg, respectively. Significant decrease of the IOP was observed at each time point of measurement as compared with the baseline IOP before adding DTFC (P = 0.01). The percent IOP reduction from the baseline IOP at week 4 and week 8 was 13.5% ± 12.3% and 11.7% ± 13.1%, respectively. The percentage of patients who achieved 10% or more IOP reduction from the baseline IOP at week 8 was 62.5%. The baseline IOP was significantly correlated with the percent IOP reduction at week 8 (P = 0.03, r = 0.34).
DTFC therapy added to PGAs as glaucoma monotherapy is effective in patients with normal tension glaucoma.
评估在正常眼压性青光眼患者中，将1.0%多佐胺/0.5%噻吗洛尔固定复方制剂（DTFC）添加到前列腺素类似物（PGA）中作为单一疗法的降眼压效果。
一项针对正常眼压性青光眼患者的前瞻性临床病例对照研究。患者此前一直每日夜间单剂量使用前列腺素（PG）进行治疗，之后在PG基础上加用DTFC治疗8周。分别在第0周（基线）、第4周和第8周上午9点测量眼压。
40例先前接受前列腺素单一疗法治疗的患者，基线眼压为15.6±2.0 mmHg。在PG基础上加用DTFC后第4周和第8周的眼压分别为13.5±2.1 mmHg和13.7±2.2 mmHg。与加用DTFC前的基线眼压相比，各测量时间点眼压均显著降低（P = 0.01）。第4周和第8周眼压较基线眼压降低的百分比分别为13.5%±12.3%和11.7%±13.1%。第8周眼压较基线眼压降低10%或更多的患者比例为62.5%。基线眼压与第8周眼压降低百分比显著相关（P = 0.03，r = 0.34）。
在正常眼压性青光眼患者中，将DTFC疗法添加到PGA中作为青光眼单一疗法是有效的。
